An update on biomarkers of heart failure in hypertensive patients

Journal of Hypertension

Volumn 30, Issue 9, 2012, Pages 1681-1689

  Gluba, Anna ^a   Bielecka, Agata ^a   Mikhailidis, Dimitri P ^b   Wong, Nathan D ^c   Franklin, Stanley S ^c   Rysz, Jacek ^a   Banach, MacIej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarkers; blood pressure; diagnosis; heart failure; hypertension

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CA 125 ANTIGEN; CARDIOTROPHIN 1; CYSTATIN C; GELATINASE A; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN DERIVATIVE; METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; PROCOLLAGEN; PROCOLLAGEN TYPE 1; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; UNCLASSIFIED DRUG; URIC ACID;

CARBOXY TERMINAL SEQUENCE; CONGESTIVE HEART FAILURE; FIBROSIS; HEART FAILURE; HUMAN; HYPERTENSION; INFORMATION PROCESSING; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; URIC ACID BLOOD LEVEL;

EID: 84865497244     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283569a9c     Document Type: Review

References (109)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95.
2. Bakhtiar R. Biomarkers in drug discovery and development. J Pharmacol Toxicol Methods 2008; 57:85-91. (Pubitemid 351384642)
3. Lainscak M, von Haehling S, Anker SD. Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MRproANP to routine biochemical markers. Int J Cardiol 2009; 132:303-311.
4. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557-1562. (Pubitemid 26154241)
5. Kenchaiah S, Pfeffer MA. Cardiac remodeling in systemic hypertension. Med Clin North Am 2004; 88:115-130. (Pubitemid 38160944)
6. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi FH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113:2089-2096.
7. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105:173-178. (Pubitemid 16039288)
8. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352.
9. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: the Framingham Heart Study. Ann Intern Med 1989; 110:101-107. (Pubitemid 19033194)
10. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566. (Pubitemid 20176696)
11. Kurata A, Shigematsu Y, Higaki J. Sex-related differences in relations of uric acid to left ventricular hypertrophy and remodeling in Japanese hypertensive patients. Hypertens Res 2005; 28:133-139. (Pubitemid 40663064)
12. Banach M, Bhatia V, Feller MA, et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol 2011; 107:1208-1214.
13. Bielecka-Dabrowa A, Rysz J, Mikhailidis DP, Banach M. What is the risk of hyperkalaemia in heart failure? Expert Opin Pharmacother 2011; 12:2329-2338.
14. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosoni E, Burnier M, Caulfield MJ, et al. European Society of Hypertension. Reappraisal of european guidelines on hypertension management: a european society of hypertension task force document. J Hypertens 2009; 27:2121-2158.
15. Karasek D, Sinkiewicz W, Blazejewski J. Relationship between Btype natriuretic peptide serum level, echocardiographic TEI index and the degree of diastolic dysfunction in patients with heart failure with preserved systolic function. Arch Med Sci 2011; 7:449-456.
16. Anker SD, Coats AJS. Metabolic, functional, and hemodynamic staging for CHF? Lancet 1996; 348:1530.
17. Patel PD, Arora RR. Uric acid and xanthine oxidase: perspectives in chronic heart failure. Arch Med Sci 2008; 4:219-225.
18. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107:1991-1997. (Pubitemid 36506072)
19. Feig DI, Kang DH, Johnson RG. Uric acid and cardiovascular risk. N Engl J Med 2008; 359:1811-1821.
20. Iliesiu A, Campeanu A, Dusceac D. Serum uric acid and cardiovascular disease. J Clin Med 2010; 5:186-192.
21. Fang J, Alderman MH. The NHANES I Epidemiologic Follow-up Study, 1971-1992. JAMA 2000; 283:2404-2410.
22. Nieto FJ, Iribarren C, Gross MD, et al. UA and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000; 148:131-139.
23. Alcaino H, Greig D, Chiong M, Verdejo H, Miranda R, Concepcion R, et al. Serum uric acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail 2008; 10:646-651.
24. Verdecchia P, Reboldi G, Schillaci G, Borgioni C, Ciucci A, Telera MP, et al. Circulating insulin and insulin-like growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 1999; 100:1802-1807. (Pubitemid 29498387)
25. Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65:1041-1049. (Pubitemid 38251080)
26. Samuelsson O, Wilhelmsen L, Pennert K, Berglund G. Angina pectoris, intermittent claudication and congestive heart failure in middleaged male hypertensives. Development and predictive factors during long-term antihypertensive care. The Primary Preventive Trial, Göteborg, Sweden. Acta Med Scand 1987; 221:23-32. (Pubitemid 17041664)
27. Ekundayo OJ, Dell'Italia LJ, Sanders PW, Arnett D, Aban I, Love TE, et al. Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol 2010; 142:279-287.
28. Saito I, Saruta T, Kondo K, et al. Serum uric acid and the reninangiotensin system in hypertension. J Am Geriatr Soc 1978; 26:241-247. (Pubitemid 8361291)
29. Krishnan E. Hyperuricemia and incident heart failure. Circulation 2009; 2:556-562.
30. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002; 105:2619-2624. (Pubitemid 34596038)
31. Lippi G, Mantagna M, Franchini M, Favaloro EJ, Targher G. The paradoxical relationship between serum acid uric and cardiovascular disease. Clin Chim Acta 2008; 392:1-7.
32. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005; 25:39-42. (Pubitemid 40128147)
33. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998; 19:1814-1822. (Pubitemid 28556651)
34. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Maciejewski M, Banach M. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit 2009; 15:MS12-MS23.
35. Athyros VG, Karagiannis A, Ganotakis ES, Paletas K, Nicolaou V, Bacharoudis G, et al. Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011; 27:1659-1668.
36. Karagiannis A, Mikhailidis DP, Tziomalos K, Sileli M, Savvatianos S, Kakafika A, et al. Serum uric acid as an independent predictor of early death after acute stroke. Circ J 2007; 71:1120-1127. (Pubitemid 46998030)
37. Tang WH, Shrestha K, Troughton RW, Borowski AG, Klein AL. Integrating plasma high-sensitivity C-reactive protein and myeloperoxidase for risk prediction in chronic systolic heart failure. Congest Heart Fail 2011; 17:105-109.
38. Navarro-Gonzalez JF, Mora C, Muros M, Jarque A, Herrera H, Garcia J. Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension. J Hypertens 2008; 26:2168-2175.
39. Mujib M, Desai R, Levitan EB, Howard V, Howard G, McGwin G, Mujib M. Prospective population studies of incident heart failure without data on baseline left ventricular ejection fraction. Arch Med Sci 2010; 6:686-688.
40. Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail 2011; 13:1087-1095.
41. Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010; 56: 225-231.
42. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 2004; 43:739-745. (Pubitemid 38405580)
43. Roselló-Llet́ E, Rivera M, Bertomeu V, Cortés R, Jordán A, González-Molinad A. Interleukin-4 and cardiac fibrosis in patients with heart failure. Rev Esp Cardiol 2007; 60:777-780.
44. López B, González A, Querejeta R, Larman M, Díez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006; 48:89-96. (Pubitemid 43929208)
45. Malyszko J, Zbroch E, Malyszko J, Mysliwiec M, Iaina A. The cardiorenal-anaemia syndrome predicts survival in peritoneally dialyzed patients. Arch Med Sci 2010; 6:539-544.
46. López B, González A, Querejeta R, Barbac J, Díez J. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications. J Hypertens 2009; 27:418-424.
47. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM, et al. Expression cloning of cardiotrophin-1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA 1995; 92:1142-1146.
48. Sheng Z, Pennica D, Wood WI, Chien KR. Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development 1996; 122:419-428. (Pubitemid 26056393)
49. López N, Díez J, Fortuño MA. Characterization of the protective effects of cardiotrophin-1 against nonischemic death stimuli in adult cardiomyocytes. Cytokine 2005;30:282-292. (Pubitemid 40775848)
50. Jougasaki M, Tachibana I, Luchner A, Leskinen H, Redfi eld MM, Burnett JC Jr. Augmented cardiac cardiotrophin-1 in experimental congestive heart failure. Circulation 2000; 101:14-17. (Pubitemid 30039070)
51. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997; 59:551-571. (Pubitemid 27142455)
52. González A, López B, Ravassa S, Beaumont J, Arias T, Hermida N, et al. Biochemical markers of myocardial remodeling in hypertensive heart disease. Cardiovasc Res 2009; 81:509-518.
53. López N, Díez J, Fortuñ MA. Differential hypertrophic effects ofcardiotrophin-1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. J Mol Cell Cardiol 2006; 41:902-913. (Pubitemid 44635572)
54. Ishikawa M, Saito Y, Miyamoto Y, Harada M, Kuwahara K, Ogawa E, et al. A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats. J Hypertens 1999; 17:807-816. (Pubitemid 29322168)
55. Ishikawa M, Saito Y, Miyamoto Y, Kuwahara K, Ogawa E, Nakagawa O, Nakao K. cDNA cloning of rat cardiotrophin-1 (CT-1): augmented expression of CT-1 gene in ventricle of genetically hypertensive rats. Biochem Biophys Res Commun 1996; 219:377-381. (Pubitemid 26090907)
56. López N, Varo N, Díez J, Fortuńo MA. Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists? Cardiovasc Res 2007; 75:536-545. (Pubitemid 47080972)
57. Banach M, Kjeldsen SE, Narkiewicz K. Controversies in hypertension treatment. Curr Vasc Pharmacol 2010; 8:731-732.
58. López B, Castellano JM, González A, Barba J, Díez J. Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension 2007; 50:977-983. (Pubitemid 350287544)
59. González A, Ravassa S, Loperena I, López B, Beaumont J, Querejeta R, et al. Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. J Hypertens 2007; 25:2148-2157. (Pubitemid 47476314)
60. González A, López B, Mart́n-Raymondi D, Lozano E, Varo N, Barba J, et al. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens 2005; 23:2297-2304. (Pubitemid 41666760)
61. López-Andrés N, Iñigo C, Gallego I, Díez J, Fortuño MA. Aldosterone induces n-1 expression in HL-1 adult cardiomyocytes. Endocrinology 2008; 149:4970-4978.
62. Yasukawa H, Hoshijima M, Gu Y, Nakamura T, Pradervand S, Hanada T, et al. Suppressor of cytokine signaling-3 is a biomechanical stressinducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. J Clin Invest 2001; 108:1459-1467. (Pubitemid 33091983)
63. Liao Z, Brar BK, Cai Q, Stephanou A, O'Leary RM, Pennica D, et al. Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and a reperfusion. Cardiovasc Res 2002; 53:902-910. (Pubitemid 34261028)
64. Monserrat L, López B, González A, Hermida M, Fernández X, Ortiz M, et al. Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. Eur Heart J 2011; 32:177-183.
65. Plaksej R, Kosmala W, Frantz S, Hermann S, Niemann M, Störk S, et al. Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure. J Hypertens 2009; 27:2483-2491.
66. Querejeta R, Varo N, López B, Larman M, Artiñano E, Etayo JC, et al. Serum carboxy-terminal propeptide of procollagentype I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101:1729-1735. (Pubitemid 30196635)
67. González A, López B, Querejeta R, Zubillaga E, Echeverría T, Díez J. Filling Pressures and Collagen Metabolism in Hypertensive Patients With Heart Failure and Normal Ejection Fraction. Hypertension 2010; 55:1418-1424.
68. Alagiakrishnan K, Banach M, Jones LG, Ahmed A, Datta S, Aronow WS. Update on diastolic heart failure or heart failure with normal ejection fraction in the elderly. Ann Med 2012; doi:10.3109/07853890.2012.660493 (in press).
69. Querejeta R, López B, González A, Sánchez E, Larman M, Marftinez Ubago JL, Díez J. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 2004; 110:1263-1268. (Pubitemid 39202343)
70. Baker KM, Chernin MI, Wixson SK, Aceto JF. Renin-angiotensin system involment in pressure overload cardiac hypertrophy in rats. Am J Physiol 1980; 259:H324-H332.
71. Komuro M, Kurabyashi M, Takuku F, Yazaki Y. Expression cellular oncogenes in the myocardium during the developmental stage and pressure overload hypertrophy of the rat heart. Circ Res 1988; 62:1075-1079.
72. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007; 117:568-575. (Pubitemid 46348511)
73. Piotrowski G, Banach M, Gerdts E, Mikhailidis DP, Hannam S, Gawor R, et al. Left atrial size in hypertension and stroke. J Hypertens 2011; 29:1988-1993.
74. Mieczkowska J, Mosiewicz J, Barud W, Kwasniewski W. Changes in the activity of connective tissue matrix enzymes in the metabolic syndrome. Arch Med Sci 2011; 7:634-641.
75. Rysz J, Banach M, Stolarek RA, Mikhailidis DP, Cialkowska-Rysz A, Pokoca L, et al. Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. Int Urol Nephrol 2011; 43:491-498.
76. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994; 23:869-877. (Pubitemid 24180829)
77. Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001; 38:1222-1226. (Pubitemid 34252835)
78. Shirakabe A, Asai K, Hata N, Yokoyama S, Shinada T, Kobayashi N, Mizuno K. Clinical significance of matrix metalloproteinase (MMP)-2 in patients with acute heart failure. Int Heart J 2010; 51:404-410.
79. Hojo Y, Ikeda U, Ueno S, Arakawa H, Shimada K. Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn Circ J 2001; 65:71-75.
80. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 2004; 10:328-333. (Pubitemid 39092685)
81. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141:211-217. (Pubitemid 32128725)
82. Lacchini R, Jacob-Ferreira ALB, Luizon MR, Gasparini S, Ferreira-Sae MCS, Schreiber R, et al. Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens 2012; 26:171-177.
83. Núñez J, Núñez E, Robles R, BoDí V, Sanchis J, Carratalá A, et al. Prognostic value of brain natriuretic peptide in acute heart failure: mortality and hospital readmission. Rev Esp Cardiol 2008; 61:1332-1337.
84. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M, ADHERE Scientific Advisory Committee, Investigators. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007; 49:1943-1950. (Pubitemid 46694287)
85. Núñez J, Núñez E, Consuegra L, Sanchis J, BoDí V, Mart́nez-Brotons A, et al. Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart 2007; 93:716-721. (Pubitemid 46808274)
86. D'Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G, Metra M, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 2003; 41:1805-1811. (Pubitemid 36584256)
87. Núñez J, Sanchis J, BoDí V, Fonarow GC, Núñez E, Bertomeu-Gonza ́lez V, et al. Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur Heart J 2010; 31:1752-1763.
88. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339:321-328. (Pubitemid 28366422)
89. Trojnarska O, Gwizdala A, Katarzynski S, Katarzynska A, Oko-Sarnowska Z, Breborowicz Z, Grajek S. Evaluation of exercise capacity with cardiopulmonary exercise testing and BNP levels in adult patients with single or systemic right ventricles. Arch Med Sci 2010; 6:192-197.
90. Suzuki M, Hamada M, Yamamoto K, Kazatani Y, Hiwada K. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 2002; 25:669-676. (Pubitemid 35153753)
91. Freitag MH, Larson MG, Levy D, Benjamin EJ, Wang TJ, Leip EP, et al. Framingham Heart Study. Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham Heart Study. Hypertension 2003; 41:978-983. (Pubitemid 36418475)
92. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, EngströmG, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009; 302:49-57.
93. Fradley MG, Larson MG, Cheng S, McCabe E, Coglianese E, Shah RV, et al. Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am J Cardiol 2011; 108:1341-1345.
94. Suzuki M, Yamamoto K, Watanabe S, Iwata T, Hamada M, Hiwada K. Association between elevated brain natriuretic peptide levels and the development of hypertrophy in patients with hypertension. Am J Med 2000; 108:627-633. (Pubitemid 30336602)
95. Coutinho T, Al-Omari M, Mosley TH Jr, Kullo IJ. Biomarkers of left ventricular hypertrophy and remodeling in blacks. Hypertension 2011; 58:920-925.
96. Varol E, Ozaydin M, Dogan A, Kosar F. Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 2005; 7:840-843. (Pubitemid 41125903)
97. Turk HM, Pekdemir H, Buyukberber S, Sevinc A, Camci C, Kocabas R, et al. Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 2003; 24:172-175. (Pubitemid 37500565)
98. Kosar F, Aksoy Y, Ozguntekin G, Ozerol I, Varol E. Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail 2006; 8:270-274. (Pubitemid 44275312)
99. Kouris NT, Zacharos ID, Kontogianni DD, Goranitou GS, Sifaki MD, Grassos HE, et al. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 2005; 7:199-203. (Pubitemid 40215613)
100. Chen YX, Wang XQ, Fang CF, Wang JF, Tang LJ. Value of BNP and tumour marker CA125 in patients with heart failure. Acta Cardiol 2008; 63:501-506.
101. Nägele H, Bahlo M, Klapdor R, Rödiger W. Fluctuations of tumor markers in heart failure patients pre and post heart transplantation. Anticancer Res 1999; 19:2531-2534. (Pubitemid 29392407)
102. Banach M, Rysz J. Current problems in hypertension and nephrology. Expert Opin Pharmacother 2010; 11:2575-2578.
103. Malyszko J, Bachorzewska-Gajewska H, Malyszko J, Iaina-Levin N, Kobus G, Dobrzycki S. Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular filtration rate. Arch Med Sci 2011; 7:658-664.
104. Shlipak MG, Sarnak MJ, Katz R, Fried L, Seliger S, Newman A, et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 2005; 45:268-271. (Pubitemid 40094736)
105. Mogensen UM, Ersbøll M, Andersen M, Andersson C, Hassager C, Torp-Pederson C, et al. Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups. Eur J Heart Fail 2011; 13:1216-1223.
106. Lassus JP, Harjola VP, Peuhkurinen K, Sund R, Mebazaa A, Siirilä K, et al., FINN-AKVA study group. Cystatin C, NTproBNP, and inflammatory markers in acute heart failure: insights into the cardiorenal syndrome. Biomarkers 2011; 16:302-310.
107. Banach M, Aronow WS. Should we have any doubts about hypertension therapy in elderly patients?: ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Pol Arch Med Wewn 2011; 121:253-258.
108. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. Curr Cardiovasc Risk Rep 2011; 5:174-179.
109. Malyszko J, Malyszko JS, Mikhailidis DP, Rysz J, Zorawski M, Banach M Hypertension and kidney disease: is renalase a new player or an innocent bystanderi J Hypertens 2012; 30:457-462.